Going forward, improvements will likely be seen in managing the side effects of CAR-T therapy as well as usage of CAR-T cells upfront as a replacement for chemotherapy or allogeneic bone marrow transplant for B-ALL. Further advances will need to reduce the biomanufacturing time needed to generate CAR-T cells as well as develop biomarkers that predict CAR-T persistence and/or toxicities.
Keyphrases
- bone marrow
- acute lymphoblastic leukemia
- induced apoptosis
- stem cell transplantation
- mesenchymal stem cells
- cell cycle arrest
- allogeneic hematopoietic stem cell transplantation
- radiation therapy
- endoplasmic reticulum stress
- signaling pathway
- combination therapy
- squamous cell carcinoma
- oxidative stress
- acute myeloid leukemia
- hematopoietic stem cell